Could a pill ease lewy body dementia? small trial tests safety
NCT ID NCT06815965
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 2a study tested an oral drug called neflamapimod in 26 people with dementia with Lewy bodies. The main goal was to check safety and how the drug moves through the body over 24 weeks. Researchers also looked at changes in thinking and memory as a secondary measure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neflamapimod (also called VX-745), a drug taken orally as a capsule
What this could lead to
If successful, this could point toward a treatment that slows or improves symptoms of dementia with Lewy bodies.
What could go wrong
This is a small, early-phase trial focused on safety, not effectiveness. The drug may not work or could have side effects like liver enzyme elevations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES (DLB) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Lariboisière - APHP; Centre de Neurologie Cognitive
Paris, 75010, France
-
Strasbourg University Hospital (Les Hopitaux Universitaires de Strasbourg)
Strasbourg, 67000, France